ES8701497A1 - Un metodo para preparar un complejo inmunogeno - Google Patents

Un metodo para preparar un complejo inmunogeno

Info

Publication number
ES8701497A1
ES8701497A1 ES548412A ES548412A ES8701497A1 ES 8701497 A1 ES8701497 A1 ES 8701497A1 ES 548412 A ES548412 A ES 548412A ES 548412 A ES548412 A ES 548412A ES 8701497 A1 ES8701497 A1 ES 8701497A1
Authority
ES
Spain
Prior art keywords
molecula
peptides
glycoside
carrier
viridas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES548412A
Other languages
English (en)
Other versions
ES548412A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES548412A0 publication Critical patent/ES548412A0/es
Publication of ES8701497A1 publication Critical patent/ES8701497A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

METODO PARA PREPARAR UN COMPLEJO INMUNOGENICO. COMPRENDE: A) PREPARAR UNA MOLECULA PORTADORA, MEZCLANDO VIRUTAS, MICROPLASMAS, BACTERIAS Y PARASITOS CON AGENTES SOLUBILIZANTES COMO ETERES DE POLIGLICOL O TUREN-20 PARA FORMAR COMPLEJOS DE AGENTE SOLUBILIZANTE Y PEPTIDOS; B) DIALIZAR EL COMPLEJO DE A) EN PRESENCIA DE UNA SOLUCION DE GLICOSIDO QUE TIENEN REGIONES HIDROFOBAS E HIDROFILAS COMO GLICOSIDO A DE CALENDULA, SAPONINA IV DE PUTRANJIA, PARA SEPARAR EL AGENTE SOLUBILIZANTE DE LOS PEPTIDOS O PROTEINAS QUE SE TRANSFIEREN A LA SOLUCION DE GLICOSIDO PARA FORMAR COMPLEJOS PROTEINICOS DE GLICOSIDO; Y C) COPULAR A LA MOLECULA PORTADORA CON MOLECULAS SELECCIONADAS ENTRE PEPTIDOS, LIPOPROTEINAS O BIOTINA, EN EL SENO DEL COMPLEJO PROTEINICO DE GLICOSIDO. LAS MOLECULAS COPULADAS A LA MOLECULA PORTADORA ESTAN SELECCIONADAS DE PEPTIDOS DE 1 A 40 PARTICULAS, DE 10 A 25 AMINOACIDOS DE LA MALARIA Y DE LA POLIO. LA MOLECULA PORTADORA HA SIDO OBTENIDA POR SELECCION DE LAS PROTEINAS DE LA MEMBRANA DE VIRUSENVOLVENTE COMO RETRO-VIRIDAS, TOJA-VIRIDAS Y HERPES-VIRIDAS. SE UTILIZA EN VACUNAS Y COMPOSICIONES INMUNOESTIMULANTES.
ES548412A 1984-11-01 1985-10-31 Un metodo para preparar un complejo inmunogeno Expired ES8701497A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8405493A SE8405493D0 (sv) 1984-11-01 1984-11-01 Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel

Publications (2)

Publication Number Publication Date
ES548412A0 ES548412A0 (es) 1986-12-01
ES8701497A1 true ES8701497A1 (es) 1986-12-01

Family

ID=20357588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES548412A Expired ES8701497A1 (es) 1984-11-01 1985-10-31 Un metodo para preparar un complejo inmunogeno

Country Status (17)

Country Link
US (1) US5254339A (es)
EP (2) EP0180564B1 (es)
JP (2) JPH07116056B2 (es)
AT (1) ATE65186T1 (es)
AU (2) AU589915B2 (es)
CA (2) CA1275042A (es)
DE (1) DE3583485D1 (es)
DK (1) DK166653B1 (es)
ES (1) ES8701497A1 (es)
FI (1) FI86801C (es)
IE (1) IE58530B1 (es)
NO (1) NO167076C (es)
NZ (1) NZ213899A (es)
PT (1) PT81384B (es)
SE (1) SE8405493D0 (es)
WO (1) WO1987002250A1 (es)
ZA (1) ZA858157B (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2598434B1 (fr) * 1986-05-12 1988-09-16 Pf Medicament Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
FR2614306B1 (fr) * 1987-04-22 1989-07-28 Pf Medicament Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant.
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
JPH049015U (es) * 1990-05-09 1992-01-27
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
JPH0756123A (ja) * 1993-08-20 1995-03-03 Nakanishi Opt:Kk 眼鏡フレーム
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
BR9606987A (pt) * 1995-01-27 1997-11-04 Genencor Int Processos para a recuperação de um produto de fermentação desejado a preparação de um pó detergente
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
EP1801591B1 (en) 1997-08-04 2016-12-28 Advanced Life Science Institute, Inc. Methods for detection or measurement of viruses
ID29082A (id) * 1998-09-22 2001-07-26 Molecular Express Inc Komposisi liposom imunogenik
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CA2366520C (en) 1999-04-09 2013-10-01 Zoetis Services Llc Anti-bacterial vaccine compositions
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2002211669A1 (en) 2000-10-12 2002-04-22 Robert Corcoran Purification of substance by reaction affinity chromatography
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60327925D1 (de) * 2002-03-01 2009-07-23 Gary Levy Verwendung von löslichem fgl2 als immunosuppressivum
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1532253B1 (en) 2002-08-12 2014-04-30 Intervet International BV Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP1578443B1 (en) 2002-11-20 2011-01-12 Bestewil Holding B.V. Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP1896067B1 (en) 2005-06-16 2011-07-20 Universiteit Gent Vaccines for immunization against helicobacter
JP5318573B2 (ja) 2005-07-28 2013-10-16 ゾエティス・ピー・エルエルシー ワクチン投与の方法、新たなネコカリシウイルス、ならびにネコパルボウイルスおよびネコヘルペスウイルスに対して動物を免疫感作する治療
PH12011502633A1 (en) 2005-10-07 2012-11-12 Zoetis P Llc Vaccines and methods to treat canine influenza
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2762163B1 (en) 2006-12-27 2018-01-03 Zoetis Services LLC Methods of vaccine administration
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
JP2011507523A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
JP5813513B2 (ja) 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
US20130251719A1 (en) 2009-10-22 2013-09-26 Tiergesundheitsdienst Bayern E.V. Bone marrow aplasia with haemorrhagic disease in calves caused by novel pathogen
ES2588225T3 (es) 2010-04-21 2016-10-31 Pharmaq As Secuencias de ácido nucleico de un virus de pece y el uso de las mismas
EP3705133B1 (en) 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN107281478B (zh) 2010-07-23 2022-04-01 诺瓦瓦克斯公司 流感疫苗
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012059593A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
NO2640832T3 (es) 2010-11-15 2018-05-19
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
DK2654784T3 (en) 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
EP2658568A1 (en) 2010-12-29 2013-11-06 Intervet International B.V. Canine babesiosis vaccine antigen
CA2822115C (en) 2010-12-29 2022-05-24 Intervet International B.V. Salmonid alphavirus protein e2
EP2691111B1 (en) 2011-03-31 2017-09-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
CA2832260C (en) 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
KR20200040899A (ko) 2011-05-13 2020-04-20 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
CA2841604C (en) * 2011-07-20 2020-01-21 Abbott Biologicals B.V. Process for producing viral antigen and vaccines
AU2012306282A1 (en) 2011-09-08 2014-03-20 Umc Utrecht Holding B.V. Vaccine based on Staphylococcal superantigen-like 3 protein (SSL3)
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
JP2015524802A (ja) 2012-07-27 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ キメラｏｓｐａ分子を含む組成物およびその使用方法
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
BR112015024391A2 (pt) 2013-03-26 2017-10-24 The Pirbright Inst mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160077214A (ko) 2013-12-16 2016-07-01 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
AU2015310932B2 (en) 2014-09-03 2018-11-22 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
BR112017006620B1 (pt) 2014-10-03 2023-12-26 Intervet International B.V Vacina, métodos para a preparação de uma vacina e para reduzir infecção por reovírus aviário, composição, e, usos de material antigênico e de uma vacina
US11725044B2 (en) 2014-10-15 2023-08-15 Xenothera Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3268743B1 (en) 2015-03-10 2020-09-02 Bio-rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
PE20220774A1 (es) 2015-05-04 2022-05-16 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
EP4494650A3 (en) 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3153265C (en) 2016-08-17 2026-01-20 Pharmaq As Sea lice vaccine
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019055463A1 (en) 2017-09-18 2019-03-21 Bayer Healthcare Llc METHODS OF INACTIVATING VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
EP4267610A1 (en) 2020-12-23 2023-11-01 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
CN113662950B (zh) * 2021-09-01 2023-03-17 山东省农业科学院畜牧兽医研究所 皂苷在制备抗牛支原体产品中的应用
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024153674A1 (en) 2023-01-18 2024-07-25 Novavax AB Methods of quantifying saponins present in particles comprising saponin and lipid
US20250085282A1 (en) 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
AU2024352706A1 (en) 2023-09-28 2026-04-02 Prokarium Limited Interleukin 18 variants
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
WO2025264964A1 (en) 2024-06-20 2025-12-26 Zoetis Services Llc Vaccines against tenacibaculum finnmarkense
WO2026022584A1 (en) 2024-07-22 2026-01-29 Glaxosmithkline Biologicals Sa Methods of delaying dementia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
GB2104527B (en) * 1981-08-24 1985-10-02 Vilas V Likhite Antingens as immunostimulant adjuvants
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP0142193A1 (en) * 1983-10-22 1985-05-22 Akzo N.V. Preparation of immunogens consisting of antigens and/or antigenic determinants bound to glycoside-containing carriers
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3617978A1 (de) * 1986-05-28 1987-12-03 Bayer Ag Verzweigte thermoplastische polycarbonate mit verbessertem schutz gegen uv-licht
US6578143B1 (en) * 1998-12-18 2003-06-10 Qualcomm Incorporated Method for negotiating weakened keys in encryption systems
FR2788649A1 (fr) * 1999-01-18 2000-07-21 Schlumberger Systems & Service Procede de chargement securise de donnees entre des modules de securite
FI20075083A0 (fi) * 2007-02-06 2007-02-06 Nokia Corp Ilmaisumenetelmä ja -laite monivuo-MIMOa varten

Also Published As

Publication number Publication date
FI854158A0 (fi) 1985-10-23
EP0242380B1 (en) 1991-04-03
DK498585D0 (da) 1985-10-30
IE58530B1 (en) 1993-10-06
EP0242380A1 (en) 1987-10-28
DK166653B1 (da) 1993-06-28
FI86801B (fi) 1992-07-15
NZ213899A (en) 1988-10-28
EP0180564A2 (en) 1986-05-07
CA1275042A (en) 1990-10-09
EP0180564A3 (en) 1988-06-01
JPS63501078A (ja) 1988-04-21
ES548412A0 (es) 1986-12-01
AU6475286A (en) 1987-05-05
SE8405493D0 (sv) 1984-11-01
DE3583485D1 (de) 1991-08-22
DK498585A (da) 1986-05-02
AU589915B2 (en) 1989-10-26
AU590904B2 (en) 1989-11-23
EP0180564B1 (en) 1991-07-17
NO167076B (no) 1991-06-24
WO1987002250A1 (en) 1987-04-23
PT81384A (en) 1985-11-01
IE852672L (en) 1986-05-01
FI86801C (fi) 1992-10-26
JPS61129136A (ja) 1986-06-17
NO167076C (no) 1991-10-02
FI854158L (fi) 1986-05-02
ZA858157B (en) 1986-06-25
JPH07116056B2 (ja) 1995-12-13
AU4938385A (en) 1986-05-08
CA1275246C (en) 1990-10-16
US5254339A (en) 1993-10-19
NO854355L (no) 1986-05-02
JPH0751514B2 (ja) 1995-06-05
ATE65186T1 (de) 1991-08-15
PT81384B (pt) 1987-11-11

Similar Documents

Publication Publication Date Title
ES8701497A1 (es) Un metodo para preparar un complejo inmunogeno
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
RU94040386A (ru) Синтетический пептид, синтетический липопептид, иммуногенный коньюгат, вектор, диагностический реагент, метод определения инфекций, антитета, способ получения олигомера, синтетическая вакцина против haemophilus influenzae, защищенный полисахарид
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
CA2102301A1 (en) Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
PT81338B (pt) Antigenios, em especial antigenios do envolucro do virus de linfoadenopatias e do sindroma de imuno-deficiencia adquirido, e virus, processo para a producao de antigenios do envolucro do virus, utilizacao destes antigenios na preparacao de composicoes imunogenicas ou no diagnostico da presenca de anticorpos contra este virus
FI885398A0 (fi) Menetelmä stabiilin, puristetussa muodossa olevan farmaseuttisen koostumuksen valmistamiseksi
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
ES539678A0 (es) Procedimiento para preparar un polipeptido ciclico
Mundy et al. Big and little forms of osteoclast activating factor
KR850001700A (ko) 단순 헤르페스 바이러스 서브유니트 왁진(Herpes Simplex Virus Subuait Vaccine)의 제조방법
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
BR9607659A (pt) Composto imunogênio composição processos para preparação de um composto imunogênico de um anticorpo anti-proteína e de um fragmento anticorpo anti-proteína e fragmento
KR930013115A (ko) Dna 분자 및 숙주
EP0095873A3 (en) Region-specific determinants for vitamin k dependent bone protein
DK0403961T3 (da) Magnetiske protein-konjugater, fremgangsmåde til deres fremstilling og deres anvendelse
GR3003097T3 (en) Immunotoxins, process for preparing them and pharmaceutical compositions containing them
ATE92075T1 (de) Verfahren zur gewinnung aktiver proteine aus einer biologisch inaktiven form.
DE69912827D1 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
DK0460446T3 (da) Koblingsreagens til peptidsyntesen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20100528